NZ217645A - Recombinant viruses expressing lav/htlv-iii related epitopes and vaccine formulations - Google Patents

Recombinant viruses expressing lav/htlv-iii related epitopes and vaccine formulations

Info

Publication number: NZ217645A
Authority: NZ; New Zealand
Prior art keywords: lav; htlv; recombinant viruses; vaccine formulations; viruses expressing
Prior art date: 1985-09-25

Application number

NZ217645A

Inventor

Hu Shiu-Lok

Anthony F Purchio

Linda Madisen

Original Assignee

Oncogen

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1985-09-25

Filing date

1986-09-22

Publication date

1991-11-26

1986-09-22 Application filed by Oncogen filed Critical Oncogen

1991-11-26 Publication of NZ217645A publication Critical patent/NZ217645A/en

Links

241000700605 Viruses Species 0.000 title 1
238000009472 formulation Methods 0.000 title 1
239000000203 mixture Substances 0.000 title 1
229960005486 vaccine Drugs 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/14011—Baculoviridae
- C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
- C12N2710/14141—Use of virus, viral particle or viral elements as a vector
- C12N2710/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
- C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
- C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
- C12N2740/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

Life Sciences & Earth Sciences (AREA)
Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Genetics & Genomics (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Biophysics (AREA)
Bioinformatics & Cheminformatics (AREA)
Biochemistry (AREA)
Zoology (AREA)
Molecular Biology (AREA)
Wood Science & Technology (AREA)
General Health & Medical Sciences (AREA)
General Engineering & Computer Science (AREA)
Virology (AREA)
Biomedical Technology (AREA)
Biotechnology (AREA)
Physics & Mathematics (AREA)
Plant Pathology (AREA)
Gastroenterology & Hepatology (AREA)
Microbiology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Medicinal Chemistry (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

NZ217645A 1985-09-25 1986-09-22 Recombinant viruses expressing lav/htlv-iii related epitopes and vaccine formulations NZ217645A (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date
US77990985A	1985-09-25	1985-09-25
US84298486A	1986-03-27	1986-03-27
US90521786A	1986-09-09	1986-09-09

Publications (1)

Publication Number	Publication Date
NZ217645A true NZ217645A (en)	1991-11-26

Family

ID=27419757

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NZ217645A NZ217645A (en)	1985-09-25	1986-09-22	Recombinant viruses expressing lav/htlv-iii related epitopes and vaccine formulations

Country Status (22)

Country	Link
CN (1)	CN1020752C (en)
AT (1)	ATA256786A (en)
CH (1)	CH676247A5 (en)
DE (1)	DE3690508T1 (en)
DK (1)	DK455486A (en)
ES (2)	ES2002490A6 (en)
FI (1)	FI863848A (en)
FR (1)	FR2587720A2 (en)
GB (1)	GB2181435B (en)
GR (1)	GR862412B (en)
HU (1)	HU205780B (en)
IE (1)	IE59314B1 (en)
IL (1)	IL80073A (en)
IT (1)	IT1195829B (en)
MY (1)	MY103182A (en)
NL (1)	NL8602422A (en)
NO (1)	NO863803L (en)
NZ (1)	NZ217645A (en)
PT (1)	PT83434B (en)
SE (4)	SE8604007L (en)
WO (1)	WO1987002038A1 (en)
YU (1)	YU46753B (en)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ATE109512T1 (en) *	1985-04-08	1994-08-15	Genetic Systems Corp	EXPRESSION AND DIAGNOSIS USING GAG-ENCODED PEPTIDES IMMUNOLOGICALLY REACTIVE WITH ANTIBODIES TO LAV.
US4734362A (en) *	1986-02-03	1988-03-29	Cambridge Bioscience Corporation	Process for purifying recombinant proteins, and products thereof
US4925784A (en) *	1986-04-04	1990-05-15	Hoffmann-La Roche Inc.	Expression and purification of an HTLV-III gag/env gene protein
US4983387A (en) *	1986-05-19	1991-01-08	Viral Technologies Inc.	HIV related peptides, immunogenic antigens, and use therefor as subunit vaccine for AIDS virus
EP0260714B1 (en) *	1986-09-19	1994-06-29	Oncogen Limited Partnership	The use of activated t-lymphocytes for preparing a pharmaceutical composition for the treatment of AIDS
IE872748L (en) *	1986-10-16	1988-04-16	Arjomari Europ	Polypeptides derived from the evvelope gene of human¹immunodeficiency virus in recombinant baculovirus infected¹insect cells
EP0272858A3 (en) *	1986-12-15	1989-07-12	Repligen Corporation	Recombinant hiv envelope proteins produced in insect cells
FR2610632B1 (en) *	1987-02-11	1990-12-21	Pasteur Institut	CHARACTERISTIC PEPTIDES OF HUMAN IMMUNODEFICIENCY RETROVIRUSES (HIV VIRUSES) THEIR APPLICATIONS IN THE DIAGNOSIS OF INFECTIONS DUE TO CERTAIN OF THESE VIRUSES AND, IF NECESSARY, IN VACCINATION AGAINST AIDS
ATE154808T1 (en) *	1987-01-16	1997-07-15	Pasteur Institut	PEPTIDES WITH THE IMMUNOLOGICAL PROPERTIES OF HIV-2
US5681713A (en) *	1987-05-08	1997-10-28	Smithkline Beecham Corporation	Expression of heterologous proteins in Drosophila cells
GB8714802D0 (en) *	1987-06-24	1987-07-29	Proteus Biotech Ltd	Synthetic polypeptides
DE10399032I1 (en) *	1987-08-28	2004-01-29	Health Research Inc	Recombinant viruses.
FR2620030B1 (en) *	1987-09-07	1990-03-23	Transgene Sa	VECTOR FOR THE EXPRESSION OF PROTEINS OF HIV-2 VIRUS, A CAUSAL AGENT FOR AIDS, CELL CULTURE INFECTED OR TRANSFORMED THROUGH THIS VECTOR, PROTEINS OBTAINED, VACCINE AND ANTIBODIES OBTAINED
IL89118A0 (en) *	1988-02-03	1989-08-15	Microgenesys Inc	Vaccine containing polypeptides derived from the envelope gene of human immunodeficiency virus type 1
US5763160A (en) *	1988-02-12	1998-06-09	United Biomedical, Inc.	Synthetic peptides and process of using same for the detection of antibodies to human immunodeficiency virus (HIV) gp120 envelope protein, diagnosis of AIDS and pre-AIDS conditions and as vaccines
ATE110112T1 (en) *	1988-05-06	1994-09-15	Ferropas Ag	METHODS AND SYSTEMS FOR THE PRODUCTION OF HIV ANTIGENS.
US5043262A (en) *	1988-05-12	1991-08-27	Dana Farber Cancer Institute	Protein, sequences containing the VPU gene therefore, vectors, methods of preparation and use
AP129A (en) *	1988-06-03	1991-04-17	Smithkline Biologicals S A	Expression of retrovirus gag protein eukaryotic cells
US5631154A (en) *	1988-06-10	1997-05-20	Therion Biologics, Incorporated	Self assembled, defective, non-self-propagating lentivirus particles
WO1989012095A1 (en) *	1988-06-10	1989-12-14	Applied Biotechnology, Inc.	A method of evaluating recombinant vaccines against immunodeficiency virus
US5747324A (en) *	1988-06-10	1998-05-05	Therion Biologics Corporation	Self-assembled, defective, non-self-propagating lentivirus particles
US5614404A (en) *	1988-06-10	1997-03-25	Theriod Biologics, Incorporated	Self-assembled, defective, non-self-propagating lentivirus particles
US5665577A (en) *	1989-02-06	1997-09-09	Dana-Farber Cancer Institute	Vectors containing HIV packaging sequences, packaging defective HIV vectors, and uses thereof
EP0469089B1 (en) *	1989-04-18	1997-11-19	Applied Biotechnology, Inc.	Generation of hybrid genes and proteins by virus-mediated recombination
ES2198400T3 (en) *	1989-06-01	2004-02-01	Applied Biotechnology, Inc.	VECTOR CODIFYING NON-SELF-PROPAGING, DEFECTIVE, SELF-ASSEMBLED VIRAL PARTICLES.
GB8923123D0 (en) *	1989-10-13	1989-11-29	Connaught Lab	A vaccine for human immunodeficiency virus
US5981276A (en) *	1990-06-20	1999-11-09	Dana-Farber Cancer Institute	Vectors containing HIV packaging sequences, packaging defective HIV vectors, and uses thereof
US5840312A (en) *	1991-05-02	1998-11-24	Institut Pasteur	Recombinant Bacillus anthracis strains unable to produce the lethal factor protein or edema factor protein
FR2676068B1 (en) *	1991-05-02	1994-11-04	Pasteur Institut	IMMUNOGENIC RECOMBINANT STRAINS OF B. ANTHRACIS - IMMUNOGENIC COMPOSITIONS CONTAINING THEM.
ATE219520T1 (en) *	1991-11-08	2002-07-15	Upjohn Co	VACCINE AGAINST FELINE LEUKEMIA VIRUS
DE4405810A1 (en)	1994-02-23	1995-08-24	Behringwerke Ag	Peptides derived from a retrovirus from the HIV group and their use
JPH11511112A (en)	1995-02-10	1999-09-28	ユニバーシティ・オブ・マサチューセッツ	Delivery of exogenous compounds
US6013506A (en) *	1995-06-05	2000-01-11	Wardley; Richard C.	Feline leukemia virus vaccines
ES2143570T3 (en) *	1995-09-06	2000-05-16	Schablonentechnik Kufstein Ag	PROCEDURE FOR THE MANUFACTURE OF A SCREENPRINT TEMPLATE.
US6723558B1 (en)	1996-01-23	2004-04-20	St. Jude Children's Research Hospital	Preparation and use of viral vectors for mixed envelope protein vaccines against human immunodeficiency viruses
US5741492A (en) *	1996-01-23	1998-04-21	St. Jude Children's Research Hospital	Preparation and use of viral vectors for mixed envelope protein vaccines against human immunodeficiency viruses
US20060165606A1 (en)	1997-09-29	2006-07-27	Nektar Therapeutics	Pulmonary delivery particles comprising water insoluble or crystalline active agents
US7871598B1 (en)	2000-05-10	2011-01-18	Novartis Ag	Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
CA2468958C (en)	2001-12-19	2012-07-03	Nektar Therapeutics	Pulmonary delivery of aminoglycosides

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ATE78293T1 (en) *	1983-05-27	1992-08-15	Texas A & M Univ Sys	METHOD OF GENERATING A RECOMBINANT BACULOVIRUS EXPRESSION VECTOR.
US4662514A (en) *	1983-11-01	1987-05-05	Charleswater Products, Inc.	Electrically conductive polymeric tubes for static sensitive electronic devices
IL76082A (en) *	1984-08-22	1991-07-18	Us Health	Molecular clones of the genome of htlv-iii and a process for the preparation thereof
US9328391B1 (en) *	1984-08-22	2016-05-03	The United States Of America As Represented By The Secretary, Department Of Health And Human Services	Cloning and expression of HIV-1 DNA
GB8501473D0 (en) *	1985-01-21	1985-02-20	Pasteur Institut	Cloned dna sequences
ATE86636T1 (en) *	1984-10-18	1993-03-15	Pasteur Institut	F ANTIGENS OF HUMAN IMMUNODEFICIENCY VIRUS AND THEIR USES.
CA1341423C (en) *	1984-10-31	2003-03-04	Paul A. Luciw	Recombinant proteins of viruses associated with lymphadenopathy syndrome and/or acquired immune deficiency syndrome
AU600658B2 (en) *	1984-12-24	1990-08-23	Genentech Inc.	Molecularly cloned acquired immunodeficiency syndrome polypeptides and their methods of use
US4774175A (en) *	1985-03-01	1988-09-27	Centocor, Inc.	Immunochemical methods for the detection of antibody against HTLV-III
NZ215867A (en) *	1985-04-19	1989-10-27	Hoffmann La Roche	Aids envelope protein, dna vectors and method of production
FR2586427B1 (en) *	1985-08-20	1988-12-09	Pasteur Institut	NUCLEOTIDE AND POLYPEPTIDE SEQUENCES FROM VISNA VIRUS AND THEIR APPLICATION TO DIAGNOSTIC TESTS AND THE PRODUCTION OF IMMUNOGENIC COMPOSITIONS

1986
- 1986-09-22 NZ NZ217645A patent/NZ217645A/en unknown
- 1986-09-22 GR GR862412A patent/GR862412B/en unknown
- 1986-09-23 IE IE252586A patent/IE59314B1/en not_active IP Right Cessation
- 1986-09-23 SE SE8604007A patent/SE8604007L/en not_active Application Discontinuation
- 1986-09-24 IT IT67730/86A patent/IT1195829B/en active
- 1986-09-24 GB GB8622987A patent/GB2181435B/en not_active Expired - Fee Related
- 1986-09-24 ES ES8602123A patent/ES2002490A6/en not_active Expired
- 1986-09-24 NO NO863803A patent/NO863803L/en unknown
- 1986-09-24 FI FI863848A patent/FI863848A/en not_active IP Right Cessation
- 1986-09-24 HU HU864072A patent/HU205780B/en not_active IP Right Cessation
- 1986-09-24 CH CH3821/86A patent/CH676247A5/fr not_active IP Right Cessation
- 1986-09-24 DK DK455486A patent/DK455486A/en not_active Application Discontinuation
- 1986-09-25 NL NL8602422A patent/NL8602422A/en not_active Application Discontinuation
- 1986-09-25 DE DE19863690508 patent/DE3690508T1/de not_active Withdrawn
- 1986-09-25 PT PT83434A patent/PT83434B/en not_active IP Right Cessation
- 1986-09-25 WO PCT/US1986/002002 patent/WO1987002038A1/en active Application Filing
- 1986-09-25 AT AT0256786A patent/ATA256786A/en unknown
- 1986-09-25 CN CN86106632A patent/CN1020752C/en not_active Expired - Fee Related
- 1986-09-25 YU YU165486A patent/YU46753B/en unknown
- 1986-09-25 FR FR8613414A patent/FR2587720A2/en active Granted
- 1986-12-31 IL IL8007386A patent/IL80073A/en not_active IP Right Cessation
1987
- 1987-09-29 MY MYPI87002188A patent/MY103182A/en unknown
1988
- 1988-05-13 ES ES8801494A patent/ES2006941A6/en not_active Expired
1991
- 1991-10-14 SE SE9102975A patent/SE9102975L/en not_active Application Discontinuation
- 1991-10-14 SE SE9102976A patent/SE9102976L/en not_active Application Discontinuation
- 1991-10-14 SE SE9102974A patent/SE9102974L/en not_active Application Discontinuation

Also Published As

Publication number	Publication date
HU205780B (en)	1992-06-29
FR2587720B2 (en)	1995-02-10
IE862525L (en)	1987-03-25
CN86106632A (en)	1987-05-13
NO863803L (en)	1987-03-26
CH676247A5 (en)	1990-12-28
IE59314B1 (en)	1994-02-09
NO863803D0 (en)	1986-09-24
DK455486A (en)	1987-03-26
GB2181435A (en)	1987-04-23
SE8604007D0 (en)	1986-09-23
FI863848A (en)	1987-03-26
GB2181435B (en)	1990-01-10
PT83434B (en)	1988-07-29
SE9102976D0 (en)	1991-10-14
IT1195829B (en)	1988-10-27
GR862412B (en)	1987-01-23
WO1987002038A1 (en)	1987-04-09
MY103182A (en)	1993-05-29
FR2587720A2 (en)	1987-03-27
SE9102975L (en)	1993-04-15
NL8602422A (en)	1987-04-16
ES2006941A6 (en)	1989-05-16
SE9102975D0 (en)	1991-10-14
IT8667730A0 (en)	1986-09-24
DE3690508T1 (en)	1988-06-23
YU165486A (en)	1989-08-31
GB8622987D0 (en)	1986-10-29
IL80073A0 (en)	1986-12-31
CN1020752C (en)	1993-05-19
ES2002490A6 (en)	1988-08-16
FI863848A0 (en)	1986-09-24
YU46753B (en)	1994-05-10
SE9102974L (en)	1993-04-15
SE8604007L (en)	1987-03-26
IL80073A (en)	1995-01-24
SE9102974D0 (en)	1991-10-14
SE9102976L (en)	1993-04-15
HUT42133A (en)	1987-06-29
PT83434A (en)	1986-10-01
ATA256786A (en)	1995-05-15
DK455486D0 (en)	1986-09-24

Publication	Publication Date	Title
NZ217645A (en)	1991-11-26	Recombinant viruses expressing lav/htlv-iii related epitopes and vaccine formulations
JPS6425800A (en)	1989-01-27	T-cell epitope of hepatities b virus nucleocapside protein
DK437883D0 (en)	1983-09-23	AROUND MICROEMULSIONS, THEIR PREPARATION AND USE
GB8907914D0 (en)	1989-05-24	Vaccine preparation
DK664187D0 (en)	1987-12-17	HYDROSOL PREPARATIONS
ATA257190A (en)	1995-07-15	VIRAL POLYPEPTIDE
EP0256878A3 (en)	1989-11-08	Vaccines
DK551187D0 (en)	1987-10-21	THERAPEUTIC PREPARATION AND ITS PREPARATION
NZ224046A (en)	1990-07-26	Hiv antigenic peptide fragments and their use
DK412787D0 (en)	1987-08-07	MEDICAL-SURGICAL POSE AND ITS PREPARATION
JPS54147692A (en)	1979-11-19	Dental bridge and its preparation
GB2203740B (en)	1991-04-17	Novel peptides, their preparation and use
IL83347A0 (en)	1987-12-31	Recombinant htlv-iii proteins and their use
DK259184D0 (en)	1984-05-25	IMMUNOGENIC PREPARATIONS
GB8616997D0 (en)	1987-02-04	Multiple-fold laser
IL81568A0 (en)	1987-09-16	Plasmids which inhibit human t-cell lymphotropic virus type iii replication
DK575787A (en)	1988-05-05	Recombinant HCMV-derived plasmid, its preparation and use
DK698188A (en)	1989-06-17	PEPTIDES, THEIR PREPARATION AND USE
PH23810A (en)	1989-11-23	Veterinary preparations
IL79740A0 (en)	1986-11-30	Hepatitis vaccine
ZA876168B (en)	1989-04-26	Human low fc epsilon-receptor,the isolation,the recombinant preparation and purification thereof
PH23582A (en)	1989-09-11	Veterinary preparations
GB2142334B (en)	1986-08-28	Immunogenic preparations
ZA883878B (en)	1990-02-28	Human immunodeficiency virus gag-encoded proteins
GB8612624D0 (en)	1986-07-02	Collapsible cot